|

Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

RECRUITINGSponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto
Actively Recruiting
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
Started2020-12-16
Est. completion2025-03
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04460950

Summary

Observational study aimed at evaluating the incidence of familial AML/MDSs in patients with de novo MDSs or AML with almost one relative affected by hematologic neoplasms and/or other cancers at young age (\< 40 years)

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient age \> 18 years old
* Diagnosis of AML or MDSs from January 2014 to December 2022
* Suspected familiarity for myeloid neoplasm: at least one family member of first or second degree affected by myeloid neoplasm or other hematological malignancy, or by solid tumors with onset at age \< 40 years or presence of signs, symptoms or laboratory tests compatible with one of the known syndromes with germinal susceptibility to AML/MDSs
* Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

* none

Conditions4

Acute Myeloid LeukemiaCancerFamilial Acute Myeloid LeukemiaMyelodysplastic Syndromes

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.